Despite testing these seven compounds against the HepG2 cell line, none of them showed any cytotoxic effect (94)
That means proper dosing, monitoring, and fewer risks
Prescriptions are issued following a review of your health information by a licensed provider
Table 3: Selected genetic causes of obesity Navigation Tips: First column and header row are frozen for easy reference Scroll horizontally and vertically to view all data Hover over rows to highlight them Use compact mode to fit more content Hover over truncated text to see full content Setmelanotide, an MC4R agonist and first-in-class treatment for hereditary obesity Setmelanotide, (Imcivree), is an MC4R agonist discovered by Ipsen SA and developed by Rhythm Pharmaceuticals that has been approved in the US since 2020 for treatment of obesity due to deficiencies of POMC, PCSK1 or LEPR confirmed by genetic testing 15 and since 2022 for syndromic obesity due to Bardet-Biedl Syndrome, a rare genetic ciliopathy 34
See our guide to stability studies for the broader framework of pharmaceutical stability testing
We did not observe a change in GLP-1 RA adherence